Otsuki Toshifumi_No.4

Q: How did the anthor address the question?

■Step1 1. In vivo KO mouse experiment testing the canonical paradigm To test whether the prevailing view which CRC buffers iron stress via the SLC7A11-GPX4 antioxidant axis holds true, intestine-specific Gpx4 knockout mice were generated. Deletion was confirmed via qPCR and western blot across all genotypes, followed by crosses into Apc single mutant, Apc;Tp53 double mutants, Apc;Tp53;Kras triple mutants. Overall survival and tumor area were evaluated. Conclusion: GPX4 is dispensable for CRC initiation and progression, showing CRC does not rely on the SLC7A11-GPX4 axis for iron stress tolerance. ■Step2 2. metabolism-focused CRISPR-cas9 screen under iron stress environment and functional validation A metabolic sgRNA library was screened from doubling 0 to 14 under vehicle, ferric ammonium citrate, or HIF2α activation. UROD, a key heme biosynthesis gene, emerged as a top hit required for CRC survival under iron stress environment. Multi-modal assays conclude that Heme acts as an essential cofactor supporting antioxidant and metabolic responses, rather than a passive iron reservoir. ■Step3 3. Multi-omics and subcellular biochemistry mapping the mechanism TMT proteomics on mitochondrial fractions identified SDHC as heme-dependent — enriched under FAC, depleted under succinyl acetone — and a thermal stability assay confirmed heme binding stabilizes it. Fractionation into whole-cell, mitochondrial, and plasma membrane compartments, validated by TOM20 and ZO-1, with HPLC quantification showed an iron-induced, Complex II–dependent rise in plasma membrane CoQ. The compartment question was then settled chemically: membrane-permeable idebenone rescued iron sensitivity, mitochondria-targeted MitoQ did not. In vivo, Sdhc shRNA CT26 tumors were smaller with elevated lipid ROS, completely reversed by Lip-1; intestine-specific Sdhc-heterozygous mice in AOM/DSS developed markedly fewer tumors with lipid ROS and 4-HNE accumulation.

kawaokashinpei3

Aug 27

2 min read

Selected journal : Cell Metabolism

Iron-addicted colorectal cancers exploit heme–complex II axis to resist oxidative cell death

https://www.cell.com/cell-metabolism/fulltext/S1550-4131(26)00185-3

What is the main question of the paper?

What metabolic adaptations allow colorectal cancer(CRC) cells to survive under iron-rich environment which is lethal for normal intestinal epithelial cells or non-CRC cells, most cells.

How did the anthor address the question?

■Step1

1. In vivo KO mouse experiment testing the canonical paradigm

To test whether the prevailing view which CRC buffers iron stress via the SLC7A11-GPX4 antioxidant axis holds true, intestine-specific Gpx4 knockout mice were generated. Deletion was confirmed via qPCR and western blot across all genotypes, followed by crosses into Apc single mutant, Apc;Tp53 double mutants, Apc;Tp53;Kras triple mutants. Overall survival and tumor area were evaluated. Conclusion: GPX4 is dispensable for CRC initiation and progression, showing CRC does not rely on the SLC7A11-GPX4 axis for iron stress tolerance.

■Step2

2. metabolism-focused CRISPR-cas9 screen under iron stress environment and functional validation

A metabolic sgRNA library was screened from doubling 0 to 14 under vehicle, ferric ammonium citrate, or HIF2α activation. UROD, a key heme biosynthesis gene, emerged as a top hit required for CRC survival under iron stress environment. Multi-modal assays conclude that Heme acts as an essential cofactor supporting antioxidant and metabolic responses, rather than a passive iron reservoir.

■Step3

3. Multi-omics and subcellular biochemistry mapping the mechanism

TMT proteomics on mitochondrial fractions identified SDHC as heme-dependent — enriched under FAC, depleted under succinyl acetone — and a thermal stability assay confirmed heme binding stabilizes it. Fractionation into whole-cell, mitochondrial, and plasma membrane compartments, validated by TOM20 and ZO-1, with HPLC quantification showed an iron-induced, Complex II–dependent rise in plasma membrane CoQ. The compartment question was then settled chemically: membrane-permeable idebenone rescued iron sensitivity, mitochondria-targeted MitoQ did not. In vivo, Sdhc shRNA CT26 tumors were smaller with elevated lipid ROS, completely reversed by Lip-1; intestine-specific Sdhc-heterozygous mice in AOM/DSS developed markedly fewer tumors with lipid ROS and 4-HNE accumulation.

What is the strength of the paper?

Each major claim is validated by two techniques whose artifacts do not overlap: shRNA against small-molecule inhibitor, genetic deletion against pharmacological block, and idebenone against MitoQ. Their data suggest iron increases SDHC protein abundance, while TCGA and CPTAC show all SDH subunits decreased in tumor. Instead of arguing, they returned to immunohistochemistry with QuPath scoring in eight patients and showed that bulk tumor profiling underestimates tumor intrinsic SDH expression, as invasive lesions are intermixed with stroma expressing negligible SDH. The discordant finding is resolved by going back to the tissue itself.

Comment

What I found most interesting is that this study moves beyond the canonical GPX4–ferroptosis framework and identifies a new heme–Complex II–CoQ antioxidant mechanism. The study builds a coherent mechanistic story from CRISPR screening to metabolic and mitochondrial analyses and finally to in vivo validation, which makes the overall conclusion quite convincing. It also highlights that the iron dependence of cancer cells is not only used to support proliferation, but is accompanied by active metabolic and antioxidant adaptations that allow them to survive in an iron-rich environment.

Comment by Du Yilin